Orlowski RZ - Search Results

1

Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma.

Baljevic M, Orlowski RZ. Baljevic M, et al. Among authors: orlowski rz. Expert Opin Drug Metab Toxicol. 2019 Jun;15(6):459-473. doi: 10.1080/17425255.2019.1621839. Expert Opin Drug Metab Toxicol. 2019. PMID: 31104525 Free PMC article. Review.

2

Proteasome inhibitors in cancer therapy.

Orlowski RZ. Orlowski RZ. Methods Mol Biol. 2005;301:339-50. doi: 10.1385/1-59259-895-1:339. Methods Mol Biol. 2005. PMID: 15917644 Review.

3

The proteasome and proteasome inhibitors in cancer therapy.

Voorhees PM, Orlowski RZ. Voorhees PM, et al. Among authors: orlowski rz. Annu Rev Pharmacol Toxicol. 2006;46:189-213. doi: 10.1146/annurev.pharmtox.46.120604.141300. Annu Rev Pharmacol Toxicol. 2006. PMID: 16402903 Review.

4

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.

Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Chanan-Khan AA, Orlowski RZ. Kuhn DJ, et al. Among authors: orlowski rz. Blood. 2007 Nov 1;110(9):3281-90. doi: 10.1182/blood-2007-01-065888. Epub 2007 Jun 25. Blood. 2007. PMID: 17591945 Free PMC article.

5

Proteasome inhibitors in cancer therapy: lessons from the first decade.

Orlowski RZ, Kuhn DJ. Orlowski RZ, et al. Clin Cancer Res. 2008 Mar 15;14(6):1649-57. doi: 10.1158/1078-0432.CCR-07-2218. Clin Cancer Res. 2008. PMID: 18347166 Review.

6

Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.

Kuhn DJ, Hunsucker SA, Chen Q, Voorhees PM, Orlowski M, Orlowski RZ. Kuhn DJ, et al. Among authors: orlowski m, orlowski rz. Blood. 2009 May 7;113(19):4667-76. doi: 10.1182/blood-2008-07-171637. Epub 2008 Dec 2. Blood. 2009. PMID: 19050304 Free PMC article.

7

Proteasome inhibitors in the treatment of multiple myeloma.

Shah JJ, Orlowski RZ. Shah JJ, et al. Among authors: orlowski rz. Leukemia. 2009 Nov;23(11):1964-79. doi: 10.1038/leu.2009.173. Epub 2009 Sep 10. Leukemia. 2009. PMID: 19741722 Free PMC article. Review.

8

Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs).

Kuhn DJ, Orlowski RZ, Bjorklund CC. Kuhn DJ, et al. Among authors: orlowski rz. Curr Cancer Drug Targets. 2011 Mar;11(3):285-95. doi: 10.2174/156800911794519725. Curr Cancer Drug Targets. 2011. PMID: 21247387 Review.

9

In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.

Chauhan D, Tian Z, Zhou B, Kuhn D, Orlowski R, Raje N, Richardson P, Anderson KC. Chauhan D, et al. Clin Cancer Res. 2011 Aug 15;17(16):5311-21. doi: 10.1158/1078-0432.CCR-11-0476. Epub 2011 Jun 30. Clin Cancer Res. 2011. PMID: 21724551 Free PMC article.

10

Proteasome inhibitors in multiple myeloma: 10 years later.

Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, Harousseau JL. Moreau P, et al. Among authors: orlowski rz. Blood. 2012 Aug 2;120(5):947-59. doi: 10.1182/blood-2012-04-403733. Epub 2012 May 29. Blood. 2012. PMID: 22645181 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

355 results

Search Page